ClinicaliQ Trial Snapshot
- A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD) — Active Not Recruiting • Phase III • NCT04849741.
- Zilganersen improves or stabilizes movement in patients with Alexander disease, a rare neurological disorder.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety and efficacy of zilganersen (ION373) in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD. Conditions: Alexander Disease Interventions: zilganersen, Placebo Lead Sponsor: Ionis Pharmaceuticals, Inc. Planned Enrollment: 54 participants